Thus, these data suggest that selective targeting of S1PR2 in cancer cells, at least in acute myeloid leukemia, bladder cancer, and melanoma, may provide an anticancer therapeutic strategy. The gene discussed is S1PR2; the disease is acute myeloid leukemia.